Paeoniflorin Attenuates Limb Ischemia by Promoting Angiogenesis Through ERα/ROCK-2 Pathway
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Paeoniflorin (PF) effectively treats peripheral artery disease (PAD) by promoting blood flow and new vessel growth. It also reduces inflammation during vascular remodeling, offering a promising therapeutic strategy.
Area Of Science
- Cardiovascular Research
- Pharmacology
- Angiogenesis Studies
Background
- Peripheral artery disease (PAD) is a serious vascular condition.
- Vascular remodeling presents a promising therapeutic avenue for PAD.
- Paeoniflorin (PF), derived from Paeonia lactiflora, is used for cardiovascular issues, but its PAD mechanisms are unknown.
Purpose Of The Study
- To investigate the therapeutic efficacy of Paeoniflorin (PF) in a mouse model of peripheral artery disease (PAD).
- To elucidate the underlying mechanisms of PF's beneficial effects on PAD, focusing on angiogenesis and inflammation.
Main Methods
- Assessed blood flow and ischemic muscle morphology in mice using laser Doppler and HE staining.
- Analyzed serologic indexes, capillary density (Lectin assay), and protein expression (Western blotting) of angiogenesis factors (VEGFA, MMP2, MMP9, ERα).
- Utilized flow cytometry to evaluate immune cell populations (macrophages, neutrophils) and investigated the ERα/ROCK2 pathway.
Main Results
- PF significantly improved blood flow, capillary density, and expression of VEGFA, MMP2, MMP9, and ERα in ischemic tissues.
- PF promoted endothelial cell migration and tube formation via the ERα/ROCK2 pathway.
- PF modulated macrophage phenotype, reducing inflammatory responses during vascular remodeling.
Conclusions
- Paeoniflorin (PF) is a potent agent for enhancing angiogenesis and reducing inflammation in revascularization processes.
- PF demonstrates significant therapeutic potential for peripheral artery disease (PAD) by targeting key mechanisms of vascular repair.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...